Champions Oncology Toekomstige groei
Future criteriumcontroles 4/6
Champions Oncology is forecast to grow earnings and revenue by 146.9% and 9.6% per annum respectively.
Belangrijke informatie
146.9%
Groei van de winst
n/a
Groei van de winst per aandeel
| Life Sciences winstgroei | 18.4% |
| Inkomstengroei | 9.6% |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 12 Sep 2024 |
Recente toekomstige groei-updates
Recent updates
Companies Like Champions Oncology (NASDAQ:CSBR) Can Afford To Invest In Growth
Oct 24
It's A Story Of Risk Vs Reward With Champions Oncology, Inc. (NASDAQ:CSBR)
Jun 14Is Now The Time To Put Champions Oncology (NASDAQ:CSBR) On Your Watchlist?
Sep 28Champions Oncology Non-GAAP EPS of -$0.02, revenue of $12.9M
Jul 21We Think Some Shareholders May Hesitate To Increase Champions Oncology, Inc.'s (NASDAQ:CSBR) CEO Compensation
Oct 14We Think Champions Oncology (NASDAQ:CSBR) Can Afford To Drive Business Growth
Jun 21Are Investors Undervaluing Champions Oncology, Inc. (NASDAQ:CSBR) By 44%?
Apr 09Here's Why We're Not At All Concerned With Champions Oncology's (NASDAQ:CSBR) Cash Burn Situation
Mar 19The Champions Oncology (NASDAQ:CSBR) Share Price Has Gained 243%, So Why Not Pay It Some Attention?
Mar 02Is There Now An Opportunity In Champions Oncology, Inc. (NASDAQ:CSBR)?
Feb 04Do Insiders Own Lots Of Shares In Champions Oncology, Inc. (NASDAQ:CSBR)?
Jan 14Philip Breitfeld Is The Chief Strategy & Innovation Officer and Director of Champions Oncology, Inc. (NASDAQ:CSBR) And They Just Sold 100% Of Their Shares
Dec 19Champions Oncology, Inc. (NASDAQ:CSBR) Analysts Are Pretty Bullish On The Stock After Recent Results
Dec 16
Champions Oncology beats on revenue
Dec 14Estimating The Fair Value Of Champions Oncology, Inc. (NASDAQ:CSBR)
Dec 04Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 4/30/2027 | 65 | N/A | -1 | N/A | 1 |
| 4/30/2026 | 59 | 1 | 0 | N/A | 1 |
| 4/30/2025 | 54 | 1 | 1 | N/A | 1 |
| 7/31/2024 | 52 | -3 | -2 | -2 | N/A |
| 4/30/2024 | 50 | -7 | -7 | -6 | N/A |
| 1/31/2024 | 49 | -10 | -7 | -5 | N/A |
| 10/31/2023 | 50 | -10 | -5 | -3 | N/A |
| 7/31/2023 | 53 | -8 | -3 | 0 | N/A |
| 4/30/2023 | 54 | -5 | 1 | 4 | N/A |
| 1/31/2023 | 54 | -3 | 3 | 5 | N/A |
| 10/31/2022 | 54 | 0 | 6 | 8 | N/A |
| 7/31/2022 | 52 | 0 | 4 | 6 | N/A |
| 4/30/2022 | 49 | 1 | 4 | 6 | N/A |
| 1/31/2022 | 47 | 0 | 1 | 4 | N/A |
| 10/31/2021 | 44 | 0 | -4 | 0 | N/A |
| 7/31/2021 | 43 | 0 | -4 | -1 | N/A |
| 4/30/2021 | 41 | 0 | -5 | -2 | N/A |
| 1/31/2021 | 39 | -1 | -1 | 3 | N/A |
| 10/31/2020 | 37 | -2 | 0 | 3 | N/A |
| 7/31/2020 | 35 | -1 | 0 | 2 | N/A |
| 4/30/2020 | 32 | -2 | 1 | 3 | N/A |
| 1/31/2020 | 31 | 0 | 0 | 1 | N/A |
| 10/31/2019 | 29 | -1 | 1 | 2 | N/A |
| 7/31/2019 | 28 | -1 | 0 | 1 | N/A |
| 4/30/2019 | 27 | 0 | 1 | 2 | N/A |
| 1/31/2019 | 24 | 0 | 1 | 2 | N/A |
| 10/31/2018 | 23 | 0 | 0 | 1 | N/A |
| 7/31/2018 | 21 | 0 | 1 | 1 | N/A |
| 4/30/2018 | 20 | -1 | N/A | -1 | N/A |
| 1/31/2018 | 19 | -3 | N/A | -1 | N/A |
| 10/31/2017 | 18 | -5 | N/A | -2 | N/A |
| 7/31/2017 | 17 | -5 | N/A | -2 | N/A |
| 4/30/2017 | 15 | -7 | N/A | -3 | N/A |
| 1/31/2017 | 15 | -7 | N/A | -4 | N/A |
| 10/31/2016 | 14 | -8 | N/A | -4 | N/A |
| 7/31/2016 | 12 | -10 | N/A | -6 | N/A |
| 4/30/2016 | 11 | -10 | N/A | -6 | N/A |
| 1/31/2016 | 12 | -12 | N/A | -8 | N/A |
| 10/31/2015 | 11 | -12 | N/A | -10 | N/A |
| 7/31/2015 | 10 | -13 | N/A | -9 | N/A |
| 4/30/2015 | 9 | -13 | N/A | -10 | N/A |
| 1/31/2015 | 8 | -12 | N/A | -7 | N/A |
| 10/31/2014 | 10 | -10 | N/A | -7 | N/A |
| 7/31/2014 | 10 | -9 | N/A | -4 | N/A |
| 4/30/2014 | 12 | -7 | N/A | -3 | N/A |
| 1/31/2014 | 11 | -7 | N/A | -5 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: CSBR is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).
Winst versus markt: CSBR is forecast to become profitable over the next 3 years, which is considered above average market growth.
Hoge groeiwinsten: CSBR is expected to become profitable in the next 3 years.
Omzet versus markt: CSBR's revenue (9.6% per year) is forecast to grow faster than the US market (8.9% per year).
Hoge groei-inkomsten: CSBR's revenue (9.6% per year) is forecast to grow slower than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if CSBR's Return on Equity is forecast to be high in 3 years time